prikaz prve stranice dokumenta Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
  Download
PDF 1.26 MB
Scientific paper - Original scientific paper
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
World Journal of Gastroenterology, 23 (2017), 29; 5304-5312. https://doi.org/10.3748/wjg.v23.i29.5304
Drmić, Domagoj; Kolenc, Danijela; Ilić, Spomenko; Bauk, Lara; Sever, Marko; Zenko Sever, Anita; Luetić, Krešimir; Šuran, Jelena; Seiwerth, Sven; Sikirić, Predrag

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Drmić, D., Kolenc, D., Ilić, S., Bauk, L., Sever, M., Zenko Sever, A. ... Sikirić, P. (2017). Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World Journal of Gastroenterology, 23. (29), 5304-5312. doi: 10.3748/wjg.v23.i29.5304

Drmić, Domagoj, et al. "Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME." World Journal of Gastroenterology, vol. 23, no. 29, 2017, pp. 5304-5312. https://doi.org/10.3748/wjg.v23.i29.5304

Drmić, Domagoj, Danijela Kolenc, Spomenko Ilić, Lara Bauk, Marko Sever, Anita Zenko Sever, Krešimir Luetić, Jelena Šuran, Sven Seiwerth and Predrag Sikirić. "Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME." World Journal of Gastroenterology 23, no. 29 (2017): 5304-5312. https://doi.org/10.3748/wjg.v23.i29.5304

Drmić, D., et al. (2017) 'Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME', World Journal of Gastroenterology, 23(29), pp. 5304-5312. doi: 10.3748/wjg.v23.i29.5304

Drmić D, Kolenc D, Ilić S, Bauk L, Sever M, Zenko Sever A, and sur.. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World Journal of Gastroenterology [Internet]. 2017 August 07 [cited 2024 April 27];23(29):5304-5312. doi: 10.3748/wjg.v23.i29.5304

D. Drmić, et al., "Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME", World Journal of Gastroenterology, vol. 23, no. 29, pp. 5304-5312, August 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:155023. [Accessed: 27 April 2024]

Metadata
Title (english)Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
AuthorDomagoj Drmić
AuthorDanijela Kolenc
AuthorSpomenko Ilić
AuthorLara Bauk
AuthorMarko Sever
AuthorAnita Zenko Sever
AuthorKrešimir Luetić
AuthorJelena Šuran
AuthorSven Seiwerth
AuthorPredrag Sikirić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
AIM: To counteract/reveal celecoxib-induced toxicity and NO system involvement. ----- METHODS: Celecoxib (1 g/kg b.w. ip) was combined with therapy with stable gastric pentadecapeptide BPC 157 (known to inhibit these lesions, 10 μg/kg, 10 ng/kg, or 1 ng/kg ip) and L-arginine (100 mg/kg ip), as well as NOS blockade [N(G)-nitro-L-arginine methyl ester (L-NAME)] (5 mg/kg ip) given alone and/or combined immediately after celecoxib. Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were assessed at 24 h and 48 h thereafter. ----- RESULTS: This high-dose celecoxib administration, as a result of NO system dysfunction, led to gastric, liver, and brain lesions and increased liver enzyme serum values. The L-NAME-induced aggravation of the lesions was notable for gastric lesions, while in liver and brain lesions the beneficial effect of L-arginine was blunted. L-arginine counteracted gastric, liver and brain lesions. These findings support the NO system mechanism(s), both NO system agonization (L-arginine) and NO system antagonization (L-NAME), that on the whole are behind all of these COX phenomena. An even more complete antagonization was identified with BPC 157 (at both 24 h and 48 h). A beneficial effect was evident on all the increasingly negative effects of celecoxib and L-NAME application and in all the BPC 157 groups (L-arginine + BPC 157; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157). Thus, these findings demonstrated that BPC 157 may equally counteract both COX-2 inhibition (counteracting the noxious effects of celecoxib on all lesions) and additional NOS blockade (equally counteracting the noxious effects of celecoxib + L-NAME). ----- CONCLUSION: BPC 157 and L-arginine alleviate gastrointestinal, liver and brain lesions, redressing NSAIDs' post-surgery application and NO system involvement.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleWorld Journal of Gastroenterology
Numberingvol. 23, no. 29, pp. 5304-5312
p-ISSN1007-9327
DOIhttps://doi.org/10.3748/wjg.v23.i29.5304
URN:NBNurn:nbn:hr:105:155023
Publication2017-08-07
Document URLhttps://doi.org/10.3748/wjg.v23.i29.5304
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:06:46